Historic Price Milestone Achieved
On 02 Sep 2026, Morepen Laboratories Ltd’s share price climbed to an intraday high of ₹110, closing near its 52-week peak of ₹110.40. This marks the highest valuation the stock has ever attained, a testament to the company’s enduring market presence and investor confidence. The day’s performance was particularly notable, with the stock advancing 7.32%, significantly outperforming the Sensex, which declined by 0.65% on the same day.
The stock’s upward momentum was further highlighted by its outperformance relative to its sector, registering a 6.15% gain compared to the Pharmaceuticals & Biotechnology sector benchmark. Trading above all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—Morepen Laboratories demonstrates a strong technical foundation supporting its price appreciation.
Impressive Short and Long-Term Performance
Morepen Laboratories Ltd’s price trajectory over various time horizons reveals a remarkable growth pattern. Over the past month, the stock surged by 95.44%, while its three-month gain stands at an extraordinary 143.18%. Year-to-date, the stock has appreciated by 171.24%, vastly outperforming the Sensex’s decline of 10.29% during the same period.
Looking further back, the company’s one-year performance shows a 129.69% increase, contrasting with the Sensex’s 4.63% decline. Over three and five years, the stock has delivered gains of 187.48% and 100.36%, respectively, both surpassing the Sensex’s corresponding returns of 16.91% and 32.14%. The decade-long performance is particularly striking, with Morepen Laboratories appreciating by 369.05%, more than double the Sensex’s 167.93% rise.
Valuation Metrics Reflect Market Confidence
As of 02 Sep 2026, at a price of ₹111.40, Morepen Laboratories trades at a price-to-earnings (P/E) ratio of 48x on a trailing twelve months (TTM) basis. The price-to-book value (P/BV) stands at 4.56x, while the enterprise value to EBITDA (EV/EBITDA) ratio is 31.54x. These multiples indicate a premium valuation consistent with the company’s growth profile and sector positioning.
The enterprise value to EBIT ratio is 39.15x, and the EV to sales ratio is 2.98x, reflecting investor willingness to pay for the company’s earnings and sales growth. The PEG ratio of 1.82x suggests that the stock’s price growth is somewhat aligned with its earnings growth rate, albeit at a premium level.
Dividend metrics reveal a modest payout, with the latest dividend declared at ₹0.2 per share and a dividend payout ratio of 9.29%. The ex-dividend date was 29 Aug 2025. Dividend yield data is not available, indicating a focus on reinvestment and growth rather than high dividend returns.
Technical Analysis Supports Bullish Trend
The overall technical trend for Morepen Laboratories Ltd is bullish, with the trend having shifted decisively on 04 Aug 2026 at a price of ₹69.21. Key technical indicators reinforce this positive outlook: the MACD, KST, Dow Theory, and moving averages all signal bullish momentum on weekly and monthly timeframes.
While the Relative Strength Index (RSI) shows bearish readings, the broader technical picture remains constructive. Bollinger Bands indicate a mildly bullish stance, and On-Balance Volume (OBV) trends are supportive on a weekly basis.
Important technical levels include immediate support at ₹33.44, the 52-week low, and resistance points at ₹89.50 (20-day moving average), ₹57.51 (100-day moving average), and ₹48.81 (200-day moving average). The stock’s recent breakthrough above these levels culminated in reaching the 52-week high of ₹110.40, now serving as a key resistance benchmark.
Delivery Volumes and Market Activity
Recent delivery volume trends indicate heightened investor participation. The one-month delivery volume increased by 135.68%, with daily delivery volumes on 01 Sep 2026 recorded at 69.56 lakh shares, representing 26.71% of total traded volume. This compares with a five-day average delivery volume of 71.92 lakh shares (29.72%) and a trailing one-month average of 88.97 lakh shares (24.05%). The previous one-month average delivery volume was significantly lower at 37.75 lakh shares (30.90%).
Quality Assessment Highlights Stability
Morepen Laboratories Ltd is classified as an average quality company based on its long-term financial performance. The management risk is assessed as average, with below-average growth metrics but an excellent capital structure. The company’s five-year sales compound annual growth rate (CAGR) stands at 8.17%, while EBIT growth over the same period is 6.76%.
Financial leverage remains low, with an average debt to EBITDA ratio of 0.49 and net debt to equity at 0.09, indicating minimal reliance on debt financing. The company maintains a healthy sales to capital employed ratio of 1.84x and a tax ratio of 21.43%. Institutional holdings are modest at 2.75%, and there is no promoter share pledging.
Return metrics show average returns on capital employed (ROCE) of 13.03% and return on equity (ROE) of 10.00%, both considered weak but stable. The dividend payout ratio of 9.29% aligns with the company’s measured approach to shareholder returns.
Short-Term Financial Trends Indicate Positive Momentum
Recent quarterly financial results demonstrate a positive trend. Profit after tax (PAT) for the latest quarter reached ₹56.40 crores, representing a substantial growth of 214.8% compared to the previous four-quarter average. Net sales for the quarter hit a record ₹570.13 crores, with profit before depreciation, interest, and tax (PBDIT) at ₹82.54 crores, the highest recorded.
The operating profit margin to net sales ratio improved to 14.48%, while profit before tax excluding other income (PBT less OI) stood at ₹69.35 crores. Earnings per share (EPS) for the quarter reached ₹1.03, marking the highest quarterly EPS to date. Cash and cash equivalents also peaked at ₹68.83 crores during the half-year period.
Despite these positives, the return on capital employed (ROCE) for the half-year was at a low of 7.60%, reflecting some pressure on capital efficiency in the short term.
Conclusion: A Milestone Reflecting Sustained Growth
Morepen Laboratories Ltd’s attainment of an all-time high share price on 02 Sep 2026 encapsulates a period of sustained growth and market outperformance. The company’s strong financial results, robust technical indicators, and solid delivery volumes underpin this achievement. While valuation multiples suggest a premium, they are consistent with the company’s growth trajectory and sector dynamics.
This milestone highlights Morepen Laboratories’ resilience and steady progress within the Pharmaceuticals & Biotechnology sector, supported by a stable quality profile and positive short-term financial trends. The stock’s performance relative to the broader market and sector benchmarks further emphasises its notable advancement over recent years.
